Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
J Cell Mol Med. 2021 Dec;25(24):11128-11141. doi: 10.1111/jcmm.17035. Epub 2021 Nov 2.
Despite the development in hepatocellular carcinoma (HCC) treatment in recent years, the therapeutic outcome of HCC remains unfavourable. This study examines the prognosis of HCC from a genetic level using clinical databases and single-cell data to identify genes with a high prognostic value. Three up-regulated genes (UBE2S, PTTG1, and CDC20) and two down-regulated genes (SOCS2 and DNASE1L3) in HCC tissues were identified. Various analyses confirmed its correlation with tumour stage (p < 0.01) and patient survival time (log-rank p < 0.001). Immune analysis, single-cell analysis, and gene set enrichment analysis (GSEA) were employed to provide insight on how they affect cancer progression, and we observed a close relation between these genes and tumour immune infiltration. Eventually, we constructed a risk score system that risk score = (0.0465) × UBE2S + (0.1851) × CDC20 + (-0.0461) × DNASE1L3 + (-0.2279) × SOCS2 (5-year area under curve = 0.706). The risk score system may serve as an effective novel prognostic system for HCC patients. This study might provide novel ideas for prognostic or therapeutic biomarkers for HCC.
尽管近年来肝细胞癌 (HCC) 的治疗取得了进展,但 HCC 的治疗效果仍然不佳。本研究从遗传水平使用临床数据库和单细胞数据来研究 HCC 的预后,以确定具有高预后价值的基因。鉴定出 HCC 组织中三个上调基因(UBE2S、PTTG1 和 CDC20)和两个下调基因(SOCS2 和 DNASE1L3)。各种分析证实了这些基因与肿瘤分期(p<0.01)和患者生存时间(对数秩 p<0.001)之间的相关性。免疫分析、单细胞分析和基因集富集分析(GSEA)用于深入了解它们如何影响癌症进展,我们观察到这些基因与肿瘤免疫浸润之间存在密切关系。最终,我们构建了一个风险评分系统,风险评分=(0.0465)×UBE2S+(0.1851)×CDC20+(-0.0461)×DNASE1L3+(-0.2279)×SOCS2(5 年 AUC=0.706)。该风险评分系统可能成为 HCC 患者的一种有效的新型预后系统。本研究可能为 HCC 的预后或治疗标志物提供新的思路。